- Thinly traded nano cap Capricor Therapeutics (NASDAQ:CAPR) jumps 28% premarket on robust volume in response to its announcement that the USPTO has issued Patent No. 9,828,603, a composition of matter patent covering pipeline candidate CAP-2003, in development for the treatment of fibrotic diseases and inflammation.
-
CAP-2003 is a regenerative medicine therapy consisting of exosomes isolated from the company's cardiosphere-derived cells. Exosomes, nano-sized membrane-enclosed vesicles secreted by cells that contain proteins, RNAs and microDNAs, act as messengers to regulate cellular processes.
- The patent was assigned to Cedars-Sinai Medical Center which granted Capricor exclusive global rights to the technology.